Drug-makers Pfizer and BioNTech said they are “within days” of seeking emergency use authorization for their COVID-19 vaccine from the U.S. Food and Drug Administration (FDA). Pfizer, an American company, and its German partner BioNTech said final results from the large Phase 3 study show the vaccine to be 95 percent effective against COVID-19. The drug-makers said there were 170 confirmed cases of COVID-19 in the study of 43,000 volunteers. Among the confirmed cases, eight received the experimental vaccine and 162 received a placebo, a shot with an inactive substance. The FDA only requires that a vaccine be at least 50 percent effective to be considered for emergency use. The agency also wants the drug-makers to present two months of safety data from the trials, which Pfizer said it had done.